Nagi Bioscience launches exclusive Priority Access Program, bringing revolutionary SydLab™ One platform to five leading academic labs for C. elegans research

Nagi Bioscience, a pioneer Swiss company pioneer in cutting-edge laboratory technologies for alternative model organisms research, proudly announces the launch of its exclusive Priority Access Program, providing access to five leading academic laboratories to the first-of-its-kind SydLab™ One platform.

Opinion | Hepatitis C Vaccine Is Essential for Expediting Elimination

Pelosi is a scientific manager and researcher. Perkins is a senior advisor in governance. Remak is a patient advocate. Seid is a vaccine program lead.

July 14, 2023

New research challenges current practices for premature babies

Giving very premature babies high concentrations of oxygen soon after birth may reduce the risk of death by 50 percent, compared to lower levels of

June 25, 2024

Another major pharma company departs BIO

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well. UCB, headquartered in

January 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.